Gelonghui May 9丨Qianhong Pharmaceutical (002550.SZ) held a performance briefing on May 9, 2024. Regarding “The company mentioned that innovative drugs have entered or are about to enter phase II clinical trials, can you give a detailed introduction to the development progress, market potential, and expected launch time of these new drugs? What strategic significance does the development of these new drugs have for the company's future development?” The company replied that the company's fastest progressing new drug project, QHRD107 (indicated for recurrent acute myeloid leukemia), is a CDK9 kinase inhibitor small molecule class 1 new drug. It has completed phase IIa clinical climbing trials and obtained encouraging initial results. It is expected to make phased progress by the end of the year. Another new macromolecule drug, QHRD106 (indicated for acute ischemic stroke), is a drug that promotes cerebrovascular circulation and stabilizes the release of active proteins to improve post-stroke healing treatment through long-term effects. It has recently conducted a Phase II clinical plan discussion and was unreservedly approved by the National New Drug Review Center. Hundreds of case enrollment tests will be carried out later.
In addition, the company also has a new small-molecule anti-tumor drug under development, QHRD110 (the preferred indication is glioma), which has completed phase I clinical trials in Australia; QHRD211 (the indication is slow growth in children lacking growth hormone) has also completed phase I clinical trials and entered phase II clinical trials. In the near future, the company will advance by leaps and bounds from the field of traditional biomedicine to the field of innovative pharmaceuticals.